CM
APLT

CM Management’s Applied Therapeutics APLT Stock Holding History

CM Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-300,000
Closed -$384K – 69
2023
Q2 		$384K Buy
+300,000
New +$398K 0.37% 59

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CM Management's APLT Position: Q3 2023 in Review

CM Management sold out of Applied Therapeutics (APLT) in Q3 2023, closing a stake of 300,000 shares — an estimated $384K sold.

CM Management first reported a position in APLT in Q2 2023 and held it in 1 quarter. The position peaked at $384K in Q2 2023. 55 funds tracked by Wall St. Rank hold APLT as of Q3 2023.

  • CM Management reported no remaining Applied Therapeutics position as of Q3 2023 after selling out during the quarter.
  • CM Management sold 300,000 Applied Therapeutics shares in Q3 2023, an estimated $384K.
  • CM Management first reported a position in Applied Therapeutics in Q2 2023 and held it in 1 quarter.
  • CM Management's Applied Therapeutics position peaked at $384K in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2023.

Based on CM Management's 13F filing for Q3 2023, filed 7 Nov 2023.